Have a feature idea you'd love to see implemented?
Let us know!
VYGR Voyager Therapeutics Inc
Price (delayed)
$5.655
Market cap
$308.91M
P/E Ratio
8.2
Dividend/share
N/A
EPS
$0.69
Enterprise value
$196.38M
Voyager Therapeutics is a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases. Voyager is committed to advancing the field of AAV gene therapy through innovation
Highlights
VYGR's equity has surged by 87% year-on-year
The revenue is up by 14% since the previous quarter and by 3.4% year-on-year
Voyager Therapeutics's net income has surged by 187% QoQ but it has shrunk by 51% YoY
Voyager Therapeutics's EPS has soared by 165% from the previous quarter but it has decreased by 48% YoY
Key stats
What are the main financial stats of VYGR
Market
Valuations
Earnings
Shares outstanding
54.63M
Market cap
$308.91M
Enterprise value
$196.38M
Price to book (P/B)
0.93
Price to sales (P/S)
2
EV/EBIT
13.04
EV/EBITDA
9.76
EV/Sales
1.2
Revenue
$163.78M
EBIT
$15.06M
EBITDA
$20.12M
Free cash flow
-$28.66M
Per share
Balance sheet
Liquidity
EPS
$0.69
Free cash flow per share
-$0.5
Book value per share
$6.06
Revenue per share
$2.83
TBVPS
$7.36
Total assets
$426.04M
Total liabilities
$95.73M
Debt
$0
Equity
$330.31M
Working capital
$329.23M
Debt to equity
0
Current ratio
8.45
Quick ratio
8.26
Net debt/EBITDA
-5.59
Margins
Efficiency
Dividend
EBITDA margin
12.3%
Gross margin
100%
Net margin
15.8%
Operating margin
5.5%
Return on assets
6.2%
Return on equity
8.3%
Return on invested capital
5.7%
Return on capital employed
3.9%
Return on sales
9.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VYGR stock price
How has the Voyager Therapeutics stock price performed over time
Intraday
4.14%
1 week
0.27%
1 month
-8.64%
1 year
-17.81%
YTD
-33%
QTD
-3.33%
Financial performance
How have Voyager Therapeutics's revenue and profit performed over time
Revenue
$163.78M
Gross profit
$163.78M
Operating income
$9.08M
Net income
$25.88M
Gross margin
100%
Net margin
15.8%
Voyager Therapeutics's net income has surged by 187% QoQ but it has shrunk by 51% YoY
The company's net margin has surged by 151% QoQ but it has shrunk by 52% YoY
The operating margin has plunged by 80% YoY
The operating income has dropped by 79% year-on-year
Growth
What is Voyager Therapeutics's growth rate over time
Valuation
What is Voyager Therapeutics stock price valuation
P/E
8.2
P/B
0.93
P/S
2
EV/EBIT
13.04
EV/EBITDA
9.76
EV/Sales
1.2
Voyager Therapeutics's EPS has soared by 165% from the previous quarter but it has decreased by 48% YoY
VYGR's equity has surged by 87% year-on-year
VYGR's price to book (P/B) is 63% lower than its 5-year quarterly average of 2.5 and 28% lower than its last 4 quarters average of 1.3
VYGR's price to sales (P/S) is 43% less than its 5-year quarterly average of 3.5 and 29% less than its last 4 quarters average of 2.8
The revenue is up by 14% since the previous quarter and by 3.4% year-on-year
Efficiency
How efficient is Voyager Therapeutics business performance
Voyager Therapeutics's return on assets has surged by 170% QoQ but it has shrunk by 67% YoY
VYGR's return on equity has surged by 152% since the previous quarter but it has dropped by 74% year-on-year
Voyager Therapeutics's ROIC has plunged by 94% YoY
Voyager Therapeutics's ROS has plunged by 72% YoY
Dividends
What is VYGR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VYGR.
Financial health
How did Voyager Therapeutics financials performed over time
VYGR's current ratio has surged by 99% year-on-year but it is down by 11% since the previous quarter
Voyager Therapeutics's quick ratio has soared by 99% YoY but it has decreased by 11% from the previous quarter
The company's debt is 100% lower than its equity
VYGR's equity has surged by 87% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.